What are the recommended loading and maintenance doses and dosing frequency for phenobarbital in adults and children?

Phenobarbital Dosing and Frequency

For status epilepticus in children, use phenobarbital IV at a loading dose of 10-20 mg/kg (maximum 1,000 mg), followed by maintenance dosing of 1-3 mg/kg IV every 12 hours; for neonates, use a loading dose of 10 mg/kg IV. 1, 2

Loading Doses by Clinical Indication

Status Epilepticus

Pediatric patients:

• Loading dose: 10-20 mg/kg IV (maximum 1,000 mg) 2
• Neonates: 10 mg/kg IV 1
• Infusion rate: Not to exceed 1 mg/kg per minute 1
• Recommended infusion time: 10-20 minutes 1

Adults:

• Loading dose: 15-20 mg/kg IV 3
• Infusion rate: Should not exceed 60 mg/min 3
• Acute convulsions: 20-320 mg IM or IV, may repeat in 6 hours as necessary 3

The 2023 ILAE neonatal seizures guidelines 4 provide moderate-quality evidence that phenobarbital at 20 mg/kg is more effective than levetiracetam (80% vs 28% seizure cessation), establishing it as the preferred first-line agent in neonates.

Anticonvulsant Therapy (Non-Status)

Pediatric maintenance:

• 4-6 mg/kg/day for 7-10 days to achieve blood levels of 10-15 mcg/mL 1
• Alternative: 10-15 mg/kg/day IM or IV 1

Maintenance Dosing

After Status Epilepticus Resolution

Pediatric:

• 1-3 mg/kg IV every 12 hours 2
• This dosing frequency is consistent across multiple 2019 guidelines for CAR T-cell therapy complications

Neonatal:

• 3-4 mg/kg/day as maintenance 5
• Do not exceed 5 mg/kg/day to avoid accumulation (plasma half-life 69-165 hours in neonates) 5

Adults:

• Daytime sedation: 30-120 mg daily in 2-3 divided doses 3
• Bedtime hypnosis: 100-320 mg 3

Critical Safety Considerations

Respiratory monitoring is mandatory: Phenobarbital increases apnea risk, particularly when combined with benzodiazepines 1. Be prepared to provide respiratory support and monitor oxygen saturation continuously 1.

Neonatal-specific concerns: Neonates have increased toxicity risk due to decreased protein binding 1. A 2004 guideline 6 noted that prophylactic phenobarbital at 20 mg/kg IM increased mortality in Kenyan children with cerebral malaria, especially when combined with multiple diazepam doses—though this risk profile differs substantially in modern intensive care settings with ventilatory support.

Hypotension risk: The 2014 ESMO palliative care guidelines 7 note that phenobarbital can cause hypotension, particularly at higher doses. The 2023 ILAE guidelines 4 reported a trend toward more hypotension with phenobarbital (17%) versus levetiracetam (5%).

Route-Specific Guidance

Intramuscular administration:

• Inject deeply into large muscle 3
• Maximum volume 5 mL at any one site 3
• Avoid injection into or near peripheral nerves (risk of permanent neurological deficit) 3

Intravenous administration:

• Use larger veins; avoid dorsum of hand or wrist 3
• Avoid varicose veins 3
• Never inject intraarterially—can cause gangrene requiring amputation 3
• Aspirate carefully before injection to avoid inadvertent arterial injection 3

Subcutaneous administration is contraindicated 3

Therapeutic Drug Monitoring

Target plasma concentrations: 15-30 mcg/mL for seizure control 5. Research data 8 in children with severe malaria showed that 15 mg/kg IV achieves concentrations >15 mg/L with good clinical effect. The 2025 ICU pharmacokinetic study 9 demonstrated high interindividual variability (81% CV on volume of distribution, 41% CV on clearance), supporting the need for TDM in critically ill patients.

Duration of Therapy

For neonatal seizures, early discontinuation after 1-2 weeks is generally possible 5. For status epilepticus, continue maintenance dosing until clinical stability is achieved, then taper gradually to avoid withdrawal seizures.